HC Wainwright Has Optimistic Outlook of DBVT FY2024 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Stock analysts at HC Wainwright raised their FY2024 EPS estimates for shares of DBV Technologies in a research report issued on Wednesday, October 23rd. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($1.41) for the year, up from their previous estimate of ($1.43). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

Several other research firms also recently commented on DBVT. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th. StockNews.com began coverage on DBV Technologies in a research note on Monday, October 21st. They set a “hold” rating for the company.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $0.87 on Friday. The firm’s 50-day simple moving average is $0.77 and its two-hundred day simple moving average is $0.96. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.28. The firm has a market cap of $83.61 million, a price-to-earnings ratio of -1.03 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same quarter last year, the business posted ($0.26) earnings per share.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.